MXPA03000073A - Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina. - Google Patents

Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.

Info

Publication number
MXPA03000073A
MXPA03000073A MXPA03000073A MXPA03000073A MXPA03000073A MX PA03000073 A MXPA03000073 A MX PA03000073A MX PA03000073 A MXPA03000073 A MX PA03000073A MX PA03000073 A MXPA03000073 A MX PA03000073A MX PA03000073 A MXPA03000073 A MX PA03000073A
Authority
MX
Mexico
Prior art keywords
somatotropin
extended release
aqueous surfactant
containing formulations
formulations
Prior art date
Application number
MXPA03000073A
Other languages
English (en)
Inventor
Yunhua N Jeng
Original Assignee
Monsanto Technology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Technology Llc filed Critical Monsanto Technology Llc
Publication of MXPA03000073A publication Critical patent/MXPA03000073A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03000073A 2000-06-26 2001-06-26 Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina. MXPA03000073A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21416800P 2000-06-26 2000-06-26
PCT/US2001/020345 WO2002000261A2 (en) 2000-06-26 2001-06-26 Surfactant-containing formulations for extended release of somatotropin

Publications (1)

Publication Number Publication Date
MXPA03000073A true MXPA03000073A (es) 2003-09-25

Family

ID=22798034

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000073A MXPA03000073A (es) 2000-06-26 2001-06-26 Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.

Country Status (5)

Country Link
US (2) US6719992B2 (es)
KR (1) KR20030023878A (es)
AU (1) AU2001271491A1 (es)
MX (1) MXPA03000073A (es)
WO (1) WO2002000261A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2406790C (en) * 2000-04-19 2009-07-07 Genentech, Inc. Sustained release formulations
ES2554106T3 (es) * 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
CA2522712A1 (en) * 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Nerve regenerating drug
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
WO2005073180A1 (ja) * 2003-12-25 2005-08-11 Kureha Corporation ヒドロキサム酸誘導体、及び該誘導体を含むａｇｅ生成阻害剤
CN101076344B (zh) 2004-09-21 2011-07-13 T·J·拉利 多用途生物材料组合物
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
KR20080009201A (ko) 2005-04-15 2008-01-25 클라루스 쎄러퓨틱스, 아이엔씨. 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물
KR100769709B1 (ko) * 2005-05-31 2007-10-23 주식회사 대웅 인성장호르몬을 함유하는 안정한 액상 제제
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
EP2049148B1 (en) 2006-07-06 2016-09-28 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
FR2919191B1 (fr) * 2007-07-25 2010-01-01 Teknimed Sas Composition adhesive pour comblement osseux a base de phosphatede calcium.
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP5487276B2 (ja) * 2012-11-12 2014-05-07 デウン カンパニー，リミテッド ヒト成長ホルモンを含有する安定した液状製剤
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2017011448A1 (en) 2015-07-13 2017-01-19 Bone Solutions, Inc. Bio-material composition and methods of use
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US4861868A (en) 1985-02-22 1989-08-29 Monsanto Company Production of proteins in procaryotes
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4977140A (en) 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
US5631227A (en) 1985-09-18 1997-05-20 The Upjohn Company Somatotropin analogs
US4917685A (en) 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4857506A (en) 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
CA1331133C (en) 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
EP0374120A3 (en) 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US5219572A (en) 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
JP3009911B2 (ja) 1989-06-28 2000-02-14 エーザイ株式会社 ペプチド又は蛋白の内服用新規製剤
AU653325B2 (en) 1990-02-12 1994-09-29 Lucky Limited A composition durably releasing bioactive polypeptides
US5182369A (en) 1990-02-28 1993-01-26 Monsanto Company Method for purifying somatotropin monomers
US5801141A (en) * 1991-06-24 1998-09-01 American Cyanamid Company Implant compositions containing a biologically active protein, peptide or polypeptide
EP0523330B1 (en) 1991-06-24 1996-03-20 American Cyanamid Company Implant compositions containing a biologically active protein, peptide or polypeptide
WO1993010758A1 (en) 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
ES2291264T3 (es) 1991-12-20 2008-03-01 Novo Nordisk A/S Formulacion farmaceutica estabilizada comprendiendo una hormona de crecimiento e histidina.
AU3582893A (en) 1992-01-13 1993-08-03 Pitman-Moore, Inc. Delayed release device for transition metal/protein complexes
EP0639984A1 (en) 1992-04-07 1995-03-01 Mallinckrodt Veterinary, Inc. Lyophilized somatotropin formulations
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
AU2592395A (en) 1994-05-19 1995-12-18 Monsanto Company Method for purifying somatotropin monomers
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
JP3086834B2 (ja) 1996-08-27 2000-09-11 松下電工株式会社 ワイヤボンディング方法
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
EP0913177A1 (de) 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6162258A (en) * 1999-08-25 2000-12-19 Osteotech, Inc. Lyophilized monolithic bone implant and method for treating bone

Also Published As

Publication number Publication date
KR20030023878A (ko) 2003-03-20
US7037516B2 (en) 2006-05-02
AU2001271491A1 (en) 2002-01-08
US6719992B2 (en) 2004-04-13
WO2002000261A3 (en) 2002-06-06
US20040171521A1 (en) 2004-09-02
US20020068693A1 (en) 2002-06-06
WO2002000261A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
MXPA03000073A (es) Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
HK1216613A1 (zh) 控釋氫可酮製劑
AU3373801A (en) Improved paste formulations
GB0218157D0 (en) Compositions for controlled release
HUP0203680A3 (en) Controlled release hydrocodone formulations
GB0025208D0 (en) Delayed release pharmaceutical formulations
IL153799A0 (en) Improved thyroid hormone formulations
SG84623A1 (en) Controlled release compositions
AU2002255865A1 (en) Photoresist compositions for short wavelength imaging
GB0015490D0 (en) Novel formulations
CA96358S (en) Locking mechanism for an extension pole
IL152533A0 (en) NOVEL FORMULATIONS OF alpha-2,4-DISULFOPHENYL-N-TERTBUTYLNITRONE
HUP0302088A3 (en) Solid amphoteric surfactants
AU2001244108A1 (en) Formulations for states of dehydration
GB0118346D0 (en) Improved semiconductor laser
AU2001238540A1 (en) Non-aqueous injectable formulations for extended release of somatotropin
EG24378A (en) Adjuvant comination formulations
AUPQ885400A0 (en) Release of sugars from biomolecules
MXPA03005933A (es) Proceso para la fabricacion de formulaciones solidas.
TW445891U (en) Improved faceplate for large game platform
GB0115893D0 (en) Formulations
GB0011333D0 (en) Controlled release formulations
GB0022027D0 (en) Disfectant formulations
GB0031831D0 (en) Process for the manufacture of solid formulations
GB0120638D0 (en) Quick release drawbar

Legal Events

Date Code Title Description
FA Abandonment or withdrawal